Friday, December 19, 2014 2:41:16 PM
Zeptepi and Alydyr, please take a good hard look at this that was named editors pick by Seeking Alpha and tell us if this is a good investment.
http://m.seekingalpha.com/article/2010691
Here's the intro to an incredibly well done article that I believe is absolute must reading.
Enjoy.
NanoViricides: House Of Cards With -80% Downside, 'Strong Sell' Recommendation
Feb. 11, 2014 9:00 AM ET | by Pump Terminator | about: nnvc
PLEASE SEE FULL DISCLOSURE IN OUR PROFILE
Aside from sounding like the name of another terrible Keanu Reeves movie, NanoViricides (NYSEMKT:NNVC) is the worst US reverse merger we have ever seen. NNVC is so obviously a vehicle designed specifically to enrich insiders we find it offensively similar to the China RTO frauds. This is the first report in a series we will release outlining the most egregious shareholder violations we are aware of in any NYSE company. With multiple questionable stock promoters NNVC has pumped the stock +330% while heavily diluting shareholders and stealing NNVC out from under public investors as insiders siphoned off millions of dollars. We also believe one of NNVC's top scientists has been dishonest which calls into question NNVC's "technology," which we believe is clearly not viable. NNVC's fair value is <$1 versus current trading price of $4.60 and is currently breaking down from the large unrestricted stock selling volume created by the (yet another) recent RDO equity sale. Our medium-term price target is $0.00 as we believe NNVC will implode once it is unable to raise cash, like the CEO, co-founder and ex-CFO's previous defunct company, SSUR.
http://m.seekingalpha.com/article/2010691
Here's the intro to an incredibly well done article that I believe is absolute must reading.
Enjoy.
NanoViricides: House Of Cards With -80% Downside, 'Strong Sell' Recommendation
Feb. 11, 2014 9:00 AM ET | by Pump Terminator | about: nnvc
PLEASE SEE FULL DISCLOSURE IN OUR PROFILE
Aside from sounding like the name of another terrible Keanu Reeves movie, NanoViricides (NYSEMKT:NNVC) is the worst US reverse merger we have ever seen. NNVC is so obviously a vehicle designed specifically to enrich insiders we find it offensively similar to the China RTO frauds. This is the first report in a series we will release outlining the most egregious shareholder violations we are aware of in any NYSE company. With multiple questionable stock promoters NNVC has pumped the stock +330% while heavily diluting shareholders and stealing NNVC out from under public investors as insiders siphoned off millions of dollars. We also believe one of NNVC's top scientists has been dishonest which calls into question NNVC's "technology," which we believe is clearly not viable. NNVC's fair value is <$1 versus current trading price of $4.60 and is currently breaking down from the large unrestricted stock selling volume created by the (yet another) recent RDO equity sale. Our medium-term price target is $0.00 as we believe NNVC will implode once it is unable to raise cash, like the CEO, co-founder and ex-CFO's previous defunct company, SSUR.
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
